Debt-to-equity of Spyre Therapeutics, Inc. from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spyre Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Spyre Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 16%, a 46% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 16% -14% -46% 30 Sep 2025
Q2 2025 20% -41% -67% 30 Jun 2025
Q1 2025 20% +427% 31 Mar 2025
Q4 2024 24% +199% 31 Dec 2024
Q3 2024 30% +127% 30 Sep 2024
Q2 2024 61% +629% 30 Jun 2024
Q1 2024 -407% -444% -1213% 31 Mar 2024
Q4 2023 -175% -209% -619% 31 Dec 2023
Q3 2023 -97% -129% -408% 30 Sep 2023
Q2 2023 -568% -597% -2042% 30 Jun 2023
Q1 2023 37% +9% +31% 31 Mar 2023
Q4 2022 34% +6% +20% 31 Dec 2022
Q3 2022 32% +8% +32% 30 Sep 2022
Q2 2022 29% +8% +39% 30 Jun 2022
Q1 2022 28% +10% +52% 31 Mar 2022
Q4 2021 28% +10% +58% 31 Dec 2021
Q3 2021 24% +2% +11% 30 Sep 2021
Q2 2021 21% -5% -18% 30 Jun 2021
Q1 2021 18% -11% -38% 31 Mar 2021
Q4 2020 18% -3% -14% 31 Dec 2020
Q3 2020 22% +5% +30% 30 Sep 2020
Q2 2020 26% +12% +86% 30 Jun 2020
Q1 2020 29% +18% +160% 31 Mar 2020
Q4 2019 21% +9% +71% 31 Dec 2019
Q3 2019 17% +6% +52% 30 Sep 2019
Q2 2019 14% +4% +35% 30 Jun 2019
Q1 2019 11% +1% +14% 31 Mar 2019
Q4 2018 12% +4% +41% 31 Dec 2018
Q3 2018 11% +4% +48% 30 Sep 2018
Q2 2018 10% +4% +55% 30 Jun 2018
Q1 2018 10% +4% +69% 31 Mar 2018
Q4 2017 9% 0% +0.82% 31 Dec 2017
Q3 2017 7% -7% -49% 30 Sep 2017
Q2 2017 7% 30 Jun 2017
Q1 2017 6% 31 Mar 2017
Q4 2016 9% 31 Dec 2016
Q3 2016 15% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.